Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119714) titled 'Safety And Preliminary Efficacy of Tizepatide Combined With Standard Protocol in Preventing Acute Graft-versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: An Early-phase Exploratory Clinical Research (TiGVHD)' on March 3.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The Second Affiliated Hospital of Nanchang University
Condition:
Acute Graft-versus-Host Disease
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-03-03
Target Sample Size: Experimental group:8;
Countries of Recruitment:
China
To know more, visit https:...